Terry Connolly, K36 Therapeutics CEO

At­las, F-Prime launch K36 Ther­a­peu­tics to ad­vance on­col­o­gy mol­e­cule for elu­sive epi­ge­net­ic tar­get

Af­ter be­ing in stealth for near­ly 11 months, a new biotech has made it­self known, com­plete with an in­flux of cash from some big-name in­vestors …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.